Literature DB >> 23918549

Is minimal residual lymph node disease in papillary thyroid cancer of prognostic impact? An analysis of the epithelial cell adhesion molecule EpCAM in lymph nodes of 40 pN0 patients.

Alexander Rehders1, Martin Anlauf, Ilona Adamowsky, Markus H Ghadimi, Sarah Klein, Christina Antke, Kenko Cupisti, Nikolas H Stoecklein, Wolfram T Knoefel.   

Abstract

This study was aimed to assess the extend of nodal microdissemination in patients with pN0 papillary thyroid carcinoma (PTC) using immunohistochemical analysis. In early stage PTC both, systematic lymphadenectomy as well as radio iodine treatment, aimed to eliminate occult nodal tumor involvement, are under controversial debate, since little is known about the extend of lymphatic microdissemination in these patients. Formalin embedded samples of the resected lymph nodes were systematically screened for the presence of disseminated tumor cells using immunohistochemistry (monoclonal antibody Ber-EP4). Clinical and histopathological parameters as well as the post-operative course were recorded. Survival data were analysed by the Kaplan-Meier method and the log rank test. Overall 321 lymph nodes of 40 patients were screened immunohistochemically. In 12.5% of the patients disseminated occult tumor cells were diagnosed. In addition to tumor resection 90% of the patients underwent adjuvant radio-iodine treatment. The mean observation period in our collective was 72 months. The detection of disseminated tumor cells did not correlate with clinicopathologic risk parameters and did not have significant influence on the prognosis of these patients. Immunohistochemical analysis enables the detection of disseminated tumor cells in patients with pN0 PTC. This finding seems to support the application of adjuvant radio iodine, even in early tumor stages.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23918549     DOI: 10.1007/s12253-013-9682-5

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  32 in total

1.  Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Steven I Sherman; R Michael Tuttle
Journal:  Thyroid       Date:  2006-02       Impact factor: 6.568

2.  Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection.

Authors:  Yasuhiro Ito; Takuya Higashiyama; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kanji Kuma; Akira Miyauchi
Journal:  World J Surg       Date:  2007-11       Impact factor: 3.352

3.  Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study.

Authors:  Catharina Ihre Lundgren; Per Hall; Paul W Dickman; Jan Zedenius
Journal:  Cancer       Date:  2006-02-01       Impact factor: 6.860

4.  Does failure to perform prophylactic level VI node dissection leave persistent disease detectable by ultrasonography in patients with low-risk papillary carcinoma of the thyroid?

Authors:  Jack M Monchik; Caroline J Simon; Diana L Caragacianu; Alan A Thomay; Vicki Tsai; Jonah Cohen; Peter J Mazzaglia
Journal:  Surgery       Date:  2009-12       Impact factor: 3.982

5.  Protein A, avidin, and biotin in immunohistochemistry.

Authors:  S M Hsu; L Raine
Journal:  J Histochem Cytochem       Date:  1981-11       Impact factor: 2.479

6.  Frequency and prognostic significance of occult tumor cells in lymph nodes in patients with adenocarcinoma of the papilla of Vater.

Authors:  P Scheunemann; N H Stoecklein; A Rehders; M Bidde; S Metz; M Peiper; C Eisenberger; J Schulte Am Esch; W T Knoefel; S B Hosch
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

7.  Risk factor analysis in differentiated thyroid cancer.

Authors:  B Cady; C E Sedgwick; W A Meissner; M S Wool; F A Salzman; J Werber
Journal:  Cancer       Date:  1979-03       Impact factor: 6.860

8.  Prognostic evaluation and review of immunohistochemically detected disseminated tumor cells in peritumoral lymph nodes of patients with pN0 colorectal cancer.

Authors:  Robert Rosenberg; Jan Friederichs; Ralf Gertler; Axel Hoos; James Mueller; Jorg Nahrig; Hjalmar Nekarda; Joerg-Ruediger Siewert
Journal:  Int J Colorectal Dis       Date:  2004-01-10       Impact factor: 2.571

9.  Papillary thyroid carcinoma: factors influencing recurrence and survival.

Authors:  Antonio Toniato; Isabella Boschin; Dario Casara; Renzo Mazzarotto; Domenico Rubello; Mariarosa Pelizzo
Journal:  Ann Surg Oncol       Date:  2008-03-07       Impact factor: 5.344

10.  Risk factors contributing to a poor prognosis of papillary thyroid carcinoma: validity of UICC/AJCC TNM classification and stage grouping.

Authors:  Yasuhiro Ito; Akira Miyauchi; Tomoo Jikuzono; Takuya Higashiyama; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kiyoshi Ichihara; Kanji Kuma
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

View more
  2 in total

1.  Immune Escape Mechanism is Impaired in the Microenvironment of Thyroid Lymph Node Metastasis.

Authors:  Lucas Leite Cunha; Suely Nonogaki; Fernando Augusto Soares; José Vassallo; Laura Sterian Ward
Journal:  Endocr Pathol       Date:  2017-12       Impact factor: 3.943

2.  EpCAM Expression in Lymph Node Metastases of Urothelial Cell Carcinoma of the Bladder: A Pilot Study.

Authors:  Christa A M van der Fels; Stefano Rosati; Igle J de Jong
Journal:  Int J Mol Sci       Date:  2017-08-18       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.